Daniel A Ninivaggi bought $27k of INDV
director at Indivior Pharmaceuticals, Inc.. 775 shares at an average of $35.39, traded Jan 5, 2026, filed Jan 7, 2026.
Score components
- +15RoleDirector
- +5Trade size$27k at market
- 0Relative to holdingsHoldings up 4.8%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001257599-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | POpen-market purchase Ordinary Shares10b5-1 | +775 | $35.39 | $27k | 16,923 | Jan 7, 2026 |
Related signals
Other insiders at Indivior Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Indivior Pharmaceuticals, Inc. | Barbara Ryan director | $249 8 shares | +0% | |
| 34Weak | Indivior Pharmaceuticals, Inc. | Stuart A Kingsley director | $30k 940 shares | +20% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Barbara Ryan director | $1,009 31 shares | +1% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Keith Humphreys director | $27k 775 shares | +15% | |
| 20Weak | Indivior Pharmaceuticals, Inc. | Mark Stejbach director | $27k 775 shares | +5% | |
| 26Weak | Indivior Pharmaceuticals, Inc. | David E. Wheadon director | $63k 1,771 shares | +14% | |
| 30Weak | Indivior Pharmaceuticals, Inc. | Barbara Ryan director | $27k 775 shares | +65% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.